Ubiquilin-2 (UBQLN2)
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Ubiquilin-2 (UBQLN2)</th>
</tr>
<tr> [@ubiquilin2018]
<td class="label">Gene</td> [@ref]
<td>[UBQLN2](/entities/ubqln2)</td> [@refa]
</tr> [@refb]
<tr> [@refc]
<td class="label">UniProt</td> [@quhd]
<td><a href="https://www.uniprot.org/uniprot/Q9UHD9" target="_blank">Q9UHD9</a></td> [@page2026]
</tr> [@allen]
<tr> [@allena]
<td class="label">PDB</td> [@allenb]
<td><a href="https://www.rcsb.org/structure/7MFU" target="_blank">7MFU</a>, <a href="https://www.rcsb.org/structure/5LRS" target="_blank">5LRS</a></td> [@allenc]
</tr> [@brainspan]
<tr> [@genes]
<td class="label">Mol. Weight</td> [@proteins]
<td>66 kDa (624 amino acids)</td> [@fusprotein]
</tr> [@psqstm]
<tr> [@sodprotein]
<td class="label">Localization</td> [@tdp]
<td>Cytoplasm, nucleus, stress granules</td> [@quhda]
</tr> [@ubiquilin]
<tr> [@ubqln]
<td class="label">Family</td> [@ubqlna]
<td>Ubiquilin family</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>Xp11.23-p11.1</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[ALS](/diseases/als), [FTD](/diseases/ftd)</td>
</tr>
</table>
Ubiquilin-2 (UBQLN2)
Introduction
Ubiquilin 2 (Ubqln2) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Ubiquilin-2 (UBQLN2) is a 66 kDa protein encoded by the single-exon UBQLN2 gene on the X chromosome (Xp11.23). It belongs to the ubiquilin family of proteins that act as shuttles in the [ubiquitin-proteasome-system](/mechanisms/ubiquitin-proteasome-system) ([UPS](/mechanisms/ubiquitin-proteasome-system), delivering polyubiquitinated substrates for proteasomal degradation [@mutations2011]. In 2011, Deng et al. identified missense mutations in UBQLN2 that cause dominant X-linked juvenile and adult-onset [als](/diseases/als) and ALS with [ftd](/diseases/ftd), establishing UBQLN2 as a critical player in Motor Neuron Disease pathogenesis [@mutations2011]. UBQLN2 is widely expressed throughout the central nervous system, with particularly high levels in motor [neurons](/entities/neurons), hippocampal [neurons](/entities/neurons), and cortical [neurons](/entities/neurons) — the cell populations most vulnerable in ALS and FTD [@key2019].
Structure
UBQLN2 is a 624 amino acid protein with a distinctive modular domain architecture [@key2019][@ubiquilin2014]:
- UBL domain (N-terminal): The ubiquitin-like domain (residues 1–54) mediates interaction with the 26S proteasome by binding to proteasomal ubiquitin receptors (Rpn10/S5a and Rpn13), enabling delivery of substrates for degradation [@ubiquilin2014].
- STI-1-like domains: Four stress-induced protein 1-like (STI-1) repeats located between residues 178–247 and 379–462. [These domains facilitate interactions with heat-shock proteins (Hsp70/Hsc70) and [autophagy](/entities/autophagy) mediators, connecting UBQLN2 to both proteasomal and autophagic degradation pathways [@key2019].
- PXX domain: A unique region containing 12 tandem PXX repeats (where P is proline and X is any amino acid). This domain, found only in UBQLN2 among the ubiquilin family, is the site of all known ALS-causing mutations and mediates protein–protein interactions critical for function [@mutations2011][@distribution2024].
- UBA domain (C-terminal): The ubiquitin-associated domain (residues 577–624) binds polyubiquitin chains on misfolded or damaged proteins, recognizing them as substrates for degradation [@ubiquilin2014].
Unlike other ubiquilin family members (UBQLN1, UBQLN3, UBQLN4), UBQLN2 contains the unique PXX repeat domain, which makes it non-redundant and essential for specific protein quality control functions in [neurons](/entities/neurons) [@key2019].
Normal Function
Under physiological conditions, UBQLN2 performs several essential functions in neuronal protein homeostasis [@key2019][@ubiquilin2014][@ubiquilin2018]:
Ubiquitin-Proteasome System Shuttle
UBQLN2 acts as an adaptor that bridges polyubiquitinated substrates (via its UBA domain) to the proteasome (via its UBL domain), facilitating efficient protein degradation. This shuttle function is critical for maintaining proteostasis in the highly metabolically active neurons of the motor [cortex](/brain-regions/cortex) and spinal cord [@ubiquilin2014].
Stress Granule Regulation
UBQLN2 plays a key role in regulating stress granule dynamics. It maintains the solubility of RNA-binding proteins such as [fus-protein](/proteins/fus-protein) in response to cellular stress, increasing the dynamics of FUS–RNA complex formation and negatively regulating stress granule assembly [@ubiquilin2018]. This function prevents the pathological conversion of reversible stress granules into irreversible protein aggregates.
Mitochondrial Protein Quality Control
UBQLN2 is required for the degradation of damaged mitochondrial outer membrane proteins and regulates mitochondrial turnover through mitophagy. This function is particularly important in motor neurons, which have high energy demands and extended axonal mitochondrial transport requirements [@mutations2011].
Autophagy Regulation
Through its STI-1 domains, UBQLN2 interacts with autophagy machinery including LC3 and p62/[p62-sqstm1](/proteins/p62-sqstm1), linking the UPS and [autophagy](/mechanisms/autophagy-lysosome-neurodegeneration) pathways. This crosstalk ensures that when proteasomal capacity is overwhelmed, substrates are redirected to autophagic degradation [@key2019].
Role in Disease
ALS and FTD Mutations
In 2011, five missense mutations in the PXX domain of UBQLN2 were identified in families with X-linked dominant ALS and ALS/FTD: P497H,
P497S, P506T, P509S, and P525S [@mutations2011]. All mutations affect proline residues within the PXX repeat region. Because
UBQLN2 is X-linked, males carrying a
single mutant allele tend to develop earlier-onset disease than heterozygous females, who may have later onset or incomplete penetrance due
to X-inactivation mosaicism [@mutations2011][@distribution2024].
Pathological Mechanisms
ALS-linked UBQLN2 mutations cause disease through several convergent mechanisms [@key2019][@distribution2024][@ubiquilin2018]:
Impaired proteasomal delivery: Mutations reduce the efficiency of UBQLN2-mediated substrate delivery to the proteasome, leading to accumulation of polyubiquitinated proteins.
Aberrant stress granule dynamics: Mutant UBQLN2 shows reduced association with FUS and other RNA-binding proteins, impairing its ability to prevent pathological stress granule conversion [@ubiquilin2018].
Defective phase separation: UBQLN2 undergoes liquid–liquid phase separation (LLPS), and ALS mutations impair stress-induced biomolecular condensate assembly, shifting the equilibrium toward solid aggregates [@key2019].
[tdp-43](/proteins/tdp-43) co-pathology: Neuropathological examination of UBQLN2 mutation carriers reveals characteristic
UBQLN2-positive and [tdp-43](/proteins/tdp-43)-positive cytoplasmic inclusions in motor neurons and hippocampal neurons [@distribution2024][@ubiquilin2014].
Beyond ALS/FTD
UBQLN2 pathology has been observed in sporadic ALS cases without
UBQLN2 mutations, suggesting broader involvement in neurodegeneration. Additionally, UBQLN2 has been shown to regulate pathological [alpha-synuclein](/proteins/alpha-synuclein), linking it to [parkinsons](/diseases/parkinsons-disease) and other [synucleinopathies](/mechanisms/synucleinopathies) [@distribution2024].
Therapeutic Targeting
UBQLN2 represents an emerging therapeutic target for ALS/FTD [@mutations2011][@ubiquilin2018]:
- Proteasome enhancement: Pharmacological upregulation of proteasome activity could compensate for UBQLN2 loss-of-function and improve clearance of aggregated proteins.
- Stress granule modulators: Compounds that prevent pathological stress granule solidification may counteract the downstream effects of UBQLN2 mutations.
- Gene therapy: Antisense oligonucleotides (ASOs) or AAV-mediated gene delivery to restore wild-type UBQLN2 function are under preclinical investigation.
- [autophagy](/mechanisms/autophagy-lysosome-neurodegeneration) induction: Enhancing autophagy through [mtor-neurodegeneration](/mechanisms/mtor-neurodegeneration)-independent pathways may compensate for impaired proteasomal degradation in UBQLN2-mutant neurons.
Brain Atlas Resources
- Allen Human Brain Atlas: [Ubiquilin-2 expression search](https://human.brain-map.org/microarray/search/show?search_term=Ubiquilin-2)
- Allen Mouse Brain Atlas: [Ubiquilin-2 search](https://mouse.brain-map.org/search/index.html?query=Ubiquilin-2)
- Allen Cell Type Atlas: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and-data/rnaseq)
- BrainSpan Developmental Transcriptome: [Ubiquilin-2 developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=Ubiquilin-2)
External Links
- [UniProt: Q9UHD8](https://www.uniprot.org/uniprot/Q9UHD8)
- [PDB: 2K3J](https://www.rcsb.org/structure/2K3J)
- [OMIM: 300264](https://www.omim.org/entry/300264)
- [UniProt: Q9UHD8](https://www.uniprot.org/uniprot/Q9UHD8)
- [PDB: 2K3J](https://www.rcsb.org/structure/2K3J)
- [OMIM: 300264](https://www.omim.org/entry/300264)
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
Background
The study of Ubiquilin 2 (Ubqln2) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
See Also
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [APP Processing](/mechanisms/app-processing)
- [Amyloid Aggregation](/mechanisms/amyloid-aggregation)
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
- [Genes Index](/genes)
- [Proteins Index](/proteins)
External Links
- [UniProt: UBQLN2](https://www.uniprot.org/uniprot/Q9UHD9)
- [AlphaFold: Ubiquilin-2 Structure](https://alphafold.ebi.ac.uk/entry/Q9UHD9)
- [OMIM: UBQLN2](https://omim.org/entry/300264)
- [GeneCards: UBQLN2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=UBQLN2)
References
[Unknown, Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia (2011)](https://doi.org/10.1038/nature10353)
[Unknown, Key role of UBQLN2 in pathogenesis of amyotrophic lateral sclerosis and Frontotemporal Dementia (2019)](https://doi.org/10.1186/s40478-019-0758-7)
[Unknown, Ubiquilin 2: a component of the ubiquitin-proteasome system with an emerging role in neurodegeneration (2014)](https://pubmed.ncbi.nlm.nih.gov/24589709/)
[Unknown, Distribution of ubiquilin 2 and TDP-43 aggregates throughout the CNS in UBQLN2-linked ALS/FTD (2024)](https://pubmed.ncbi.nlm.nih.gov/38115557/)
[Unknown, Ubiquilin 2 modulates ALS/FTD-linked FUS–RNA complex dynamics and stress granule formation (2018)](https://doi.org/10.1073/pnas.1811997115)
[Unknown, (n.d.)](https://doi.org/10.1042/BST20241073)
[Unknown, (n.d.)](https://pubmed.ncbi.nlm.nih.gov/34129687/)
[Unknown, (n.d.)](https://pubmed.ncbi.nlm.nih.gov/22717235/)
[Unknown, (n.d.)](https://doi.org/10.1038/s41598-022-26899-0)
Unknown, Q9UHD9 — UBQLN2 (n.d.)
Unknown, Page auto-generated from NeuroWiki protein database. Last updated: 2026-02-27. (2026)
-, Allen Brain Atlas (n.d.)
-, Allen Human Brain Atlas: Ubiquilin-2 search (n.d.)
-, Allen Mouse Brain Atlas: Ubiquilin-2 search (n.d.)
-, Allen Cell Type Atlas (n.d.)
-, BrainSpan Developmental Transcriptome (n.d.)
Unknown, - [Genes Index (n.d.)
Unknown, - [Proteins Index (n.d.)
Unknown, - fus-protein (n.d.)
Unknown, - p62-sqstm1 (n.d.)
Unknown, - sod1-protein (n.d.)
Unknown, - tdp-43## External Links (n.d.)
- UniProt:, Q9UHD9 (n.d.)
- AlphaFold:, Ubiquilin-2 Structure Prediction (n.d.)
- OMIM:, 300264 — UBQLN2 (n.d.)
- GeneCards:, UBQLN2 (n.d.)